Jeito Life is a biotechnology company focused on the development and acceleration of drug candidates with the aim of providing innovative treatments for patients with high unmet medical needs. The company leverages a unique business model that combines venture capital investment with in-house drug development expertise.

Jeito Life

Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. We empower and support entrepreneurs through our expert, integrated, multi-talented team.

Jeito Capital is based in Paris with a presence in Europe and the United States.

Follow us to get our latest news & job offers.

Neogene Therapeutics

JEITO

We are thrilled to share that JEITO has been ranked by Private Equity Magazine as the 2nd leading French growth fund for its investments in  European companies and 4th in French companies in 2023. 
 
These rankings highlight our steady commitment to support the French and European biopharmaceutical ecosystem and our ambition to build global market leaders able to bring faster innovations to patients with high unmet need.
 
Our journey goes on! 🚀
 
#FasterForThePatient #privateequity #growth #biopharma #innovation #healthcare

Corteria Pharmaceuticals' lead asset, aimed at treating worsening heart failure, is now advancing to clinical trials! 🔬

We are delighted to share that our portfolio company, focused on the development of transformative therapies for heart failure and obesity, today announced that it has initiated a Phase 1 study to evaluate its first-in-class corticotropin-releasing hormone receptor in both healthy volunteers and patients with chronic heart failure.

After preclinical studies that showed that Corteria's lead asset has demonstrated substantial protective effects and functional improvement in the heart, vasculature, and kidneys, this new step is another great achievement for Corteria.

The challenge of discovering new treatments is substantial, given that 60 million people are living with heart failure.

Congratulations to the Corteria Pharmaceuticals team on launching this new phase.


#FasterForThePatient #heartfailure #biopharma #innovation

Two major announcements in just two days for NMD Pharma A/S, our portfolio company developing novel treatments for patients living with neuromuscular diseases ⬇️
 
1️⃣  NMD Pharma A/S has received clearance from the US FDA for our Investigational New Drug (IND) application to initiate a Phase 2b clinical trial of NMD670 in patients with generalized Myasthenia Gravis. Learn more about this trial 👉 https://lnkd.in/eTGqitRd
 
2️⃣  Plus, the company has been reviewed and published by Science Translational Medicine. The paper introduces new data that, for the first time, establish CIC-1 chloride channel inhibition as a novel and highly translational therapeutic approach to improve persistent and severe symptoms in patients with Myasthenia Gravis. 
 
Watch NMD Pharma's CEO Thomas Holm Pedersen detailing the study's findings: https://lnkd.in/egDHvQ3P

Congratulations to NMD Pharma A/S on these two significant achievements 👏
 
#FasterForThePatient #lifesciences #biopharma #clinicaltrial #neuromusculardisease

New milestone for HI-Bio! 🚀

Our clinical-stage portfolio company today announced that the U.S. FDA has granted Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients.

AMR is a major cause of kidney transplant failure, with late AMR affecting approximately 23,000 patients total in the U.S. There is no effective treatment for AMR and patient options are highly limited.

HI-Bio is committed to advancing felzartamab across a spectrum of immune-mediated diseases, including IgA nephropathy, lupus nephritis and primary membranous nephropathy.

This news comes 5 months after being granted Breakthrough Therapy by the FDA for Felzartamab in primary membranous nephropathy (PMN).

Congratulations to Hi-Bio team for this new milestone 👏

Read more 👉 https://lnkd.in/eiG8EraB

#FasterForThePatient #immunology #FDA #lifesciences #biopharma

On Tuesday, JEITO joined the first BioLabs European Investor Day in Paris, as part of Hello Tomorrow Deep Tech Days! 

Representing our fund, Mehdi AINOUCHE extended his support to entrepreneurs innovating in healthcare, highlighting Jeito's contribution to the ecosystem. 

In a few words, JEITO is:

➡ More than 15 investments in 9 therapeutic areas in diversified development stage
➡ A unique support for companies, operational and strategic to accelerate their development to patients and commercialisation 
➡ A team of experts across the entire drug value chain extended to leading international Special Advisors 
➡ A mission: to accelerate innovation for patients with high unmet needs
 
Thank you to BioLabs France, Hello Tomorrow, and all the participants.
 
#BioLabsEuropeanInvestorDay #GoFasterForThePatient #InvestorDay #PrivateEquity #LifeSciences #Biopharma

LIFE:JEITO

Jeito Life